top of page

NEWS & INSIGHTS

Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

🧬 Biopharma Bite Sized News 🍪 April 22nd - April 26th

BEQVEZ™ Gene Tx Approved & 9 more major updates...👇


Want a list of segmented biopharma companies or access to our online platform? Get more info about our data and how it can help with sales and market intelligence


🎯 → Approvals

🔬 → New data

🤝 → M&A activity


Pfizer 

🎯 FDA approved BEQVEZ™ (fidanacogene elaparvovec-dzkt), a one-time gene therapy for adults with Hemophilia B.


Amneal Pharmaceuticals 

🎯 Received FDA approval for OTC Naloxone Hydrochloride nasal spray for emergency treatment of an opioid overdose.


ImmunityBio 

🎯 FDA approved ANKTIVA® for BCG-unresponsive non-muscle invasive bladder cancer.


Gilead

🎯 FDA approved Biktarvy® label update with data for pregnant adults with HIV.


BeiGene 

🎯 Received European Comm. approval for Tislelizumab as treatment for NSCLC.


AstraZeneca

🎯 Voydeya approved in the EU as an add-on treatment to ravulizumab or eculizumab for adults with the rare disease PNH who have residual hemolytic anemia.


Legend Biotech

🎯 EU Comm. approved CARVYKTI® (ciltacabtagene autoleucel) as second-line treatment for r/r MM. 


Sensei Biotherapeutics 

🔬 Preliminary topline results from the Ph1 DE study of SNS-101, both as a standalone treatment and in combination with cemiplimab, will be presented at ASCO 6/1/24. 


Immutep 

🔬 Reported preliminary topline result from cohort B of the TACTI-003 Ph2b trial of eftilagimod alpha (efti) + KEYTRUDA® showing a preliminary response rate of 26.9% achieving the primary endpoint of the study. Further data will be released in H1 2024.  


Incyte & Escient Pharmaceuticals 

🤝 Acquired Escient Pharmaceuticals for $750M acquiring its pipeline of first-in-class oral MRGPR antagonists.





---


Interested in these updates? Get the full update each week → https://www.biopharmiq.com/#subscribe 



Data:

April 22-26, 2024


Article History:

RF, DV (04/26/24)

댓글


bottom of page